Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs

Journal of Alzheimer's Disease

Volumn 26, Issue 1, 2011, Pages 143-155

  Araujo, Joseph A ^a,b,c   Greig, Nigel H ^d   Ingram, Donald K ^e   Sandin, Johan ^f   De Rivera, Christina ^a,b   Milgram, Norton W ^a,b,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b CanCog Technologies Incorporated   (Canada)

^c InterVivo Solutions Inc   (Canada)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^f ASTRAZENECA R AND D   (Sweden)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; cholinesterase inhibitor; dog; donepezil; learning; memory; phenserine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PHENSERINE; PLACEBO; SCOPOLAMINE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DISCRIMINATION LEARNING; DOG; FEMALE; LEARNING; MALE; MEMORY; NONHUMAN; PRIORITY JOURNAL; SCREENING; TASK PERFORMANCE; VALIDATION STUDY; WORKING MEMORY;

EID: 80052845637     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110005     Document Type: Article

References (96)

1. Woodruff-Pak DS (2008) Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 15, 507-521.
2. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW (1996) Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 66, 11-23. (Pubitemid 26195731)
3. Cummings BJ, Satou T, Head E, Milgram NW, Cole GM, Savage MJ, Podlisny MB, Selkoe DJ, Siman R, Greenberg BD, Cotman CW (1996) Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Neurobiol Aging 17, 653-659.
4. Head E, Callahan H, Muggenburg BA, Cotman CW, Milgram NW (1998) Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging 19, 415-425. (Pubitemid 29065491)
5. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW (2000) Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging 21, 89-96. (Pubitemid 30224790)
6. Tapp PD, Head K, Head E, Milgram NW, Muggenburg BA, Su MY (2006) Application of an automated voxel-based mor-phometry technique to assess regional gray and white matter brain atrophy in a canine model of aging. Neuroimage 29, 234-244. (Pubitemid 41828046)
7. Tapp PD, Siwak CT, Gao FQ, Chiou JY, Black SE, Head E, Muggenburg BA, Cotman CW, Milgram NW, Su MY (2004) Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. J Neurosci 24, 8205-8213. (Pubitemid 39280799)
8. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW (2008) Region specific neuron lossinthe aged canine hippocampus is reduced by enrichment. Neurobiol Aging 29, 39-50. (Pubitemid 350102716)
9. Siwak-Tapp CT, Head E, Muggenburg BA, Milgram NW, Cotman CW (2007) Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem 88, 249-259. (Pubitemid 47223756)
10. Head E, Liu J, Hagen TM, Muggenburg BA, Milgram NW, Ames BN, Cotman CW (2002) Oxidative damage increases with ageinacanine modelofhuman brain aging.J Neurochem 82, 375-381. (Pubitemid 34774628)
11. Su MY, Head E, Brooks WM, Wang Z, Muggenburg BA, Adam GE, Sutherland R, Cotman CW, Nalcioglu O (1998) Magnetic resonance imaging of anatomic and vascular characteristics in a canine model of human aging. Neurobiol Aging 19, 479-485. (Pubitemid 29065497)
12. Pugliese M, Mascort J, Mahy N, Ferrer I (2006) Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neu-ropathol 112, 175-183.
13. Chan AD, Nippak PM, Murphey H, Ikeda-Douglas CJ, Muggenburg B, Head E, Cotman CW, Milgram NW (2002) Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility. Behav Neurosci 116, 443-454. (Pubitemid 34533580)
14. Head E, Mehta R, Hartley J, Kameka M, Cummings BJ, Cot-man CW, Ruehl WW, Milgram NW (1995) Spatial learning and memory as a function of age in the dog. Behav Neurosci 109, 851-858.
15. Studzinski CM, Christie LA, Araujo JA, Burnham WM, Head E, Cotman CW, Milgram NW (2006) Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. Neurobiol Learn Mem 86, 197-204. (Pubitemid 44287579)
16. Milgram NW, Adams B, Callahan H, Head E, Mackay B, Thirlwell C, Cotman CW (1999) Landmark discrimination learning in the dog. Learn Mem 6, 54-61. (Pubitemid 29164546)
17. Milgram NW, Head E, Weiner E, Thomas E (1994) Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Behav Neurosci 108, 57-68. (Pubitemid 24097744)
18. Milgram NW, Zicker SC, Head E, Muggenburg BA, Murphey H, Ikeda-Douglas CJ, Cotman CW (2002) Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 23, 737-745. (Pubitemid 35217699)
19. Tapp PD, Siwak CT, Estrada J, Head E, Muggenburg BA, Cotman CW, Milgram NW (2003) Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem 10, 64-73. (Pubitemid 36177022)
20. Tapp PD, Siwak CT, Estrada J, Holowachuk D, Milgram NW (2003) Effects of age on measures of complex working memory span in the beagle dog (Canis familiaris) using two versions of a spatial list learning paradigm. Learn Mem 10, 148-160. (Pubitemid 36418725)
21. Siwak CT, Tapp PD, Milgram NW (2001) Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog. Learn Mem 8, 317-325. (Pubitemid 34037575)
22. Siwak CT, Tapp PD, Zicker SC, Murphey HL, Muggenburg BA, Head E, Cotman CW, Milgram NW (2003) Locomotor activity rhythms in dogs vary with age and cognitive status. Behav Neurosci 117, 813-824. (Pubitemid 36935391)
23. Adams B, Chan A, Callahan H, Milgram NW (2000) The canine as a model of human cognitive aging: recent developments. Prog Neuropsychopharmacol Biol Psychiatry 24, 675-692. (Pubitemid 30640154)
24. Cotman CW, Head E, Muggenburg BA, Zicker S, Milgram NW (2002) Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging 23, 809-818. (Pubitemid 35217705)
25. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D (2008) A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 28, 3555-3566.
26. Studzinski CM, Araujo JA, Milgram NW (2005) The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuropsychophar-macol Biol Psychiatry 29, 489-498. (Pubitemid 40417601)
27. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The choliner-gic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
28. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decar-boxylase activities in necropsy brain tissue. J Neurol Sci 34, 247-265. (Pubitemid 8188071)
29. Perry EK, Perry RH, Blessed G, Tomlinson BE (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1, 189. (Pubitemid 8020501)
30. Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4, 273-277. (Pubitemid 9001675)
31. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2, 1457-1459. (Pubitemid 9061468)
32. Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fair-bairn AF, Tomlinson BE (1983) Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 59, 277-289. (Pubitemid 13113569)
33. Davies P, Maloney AJ (1976) Selective loss of central cholin-ergic neurons in Alzheimer's disease. Lancet 2, 1403. (Pubitemid 8004505)
34. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 50, 1914-1923.
35. Mulugeta E, Karlsson E, Islam A, Kalaria R, Mangat H, Winblad B, Adem A (2003) Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 960, 259-262. (Pubitemid 36044584)
36. Reinikainen KJ, Riekkinen PJ, Halonen T, Laakso M (1987) Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease. Life Sci 41, 453-461. (Pubitemid 17105224)
37. Rinne JO, Laakso K, Lonnberg P, Molsa P, Paljarvi L, Rinne JK, Sako E, Rinne UK (1985) Brain muscarinic receptors in senile dementia. Brain Res 336, 19-25. (Pubitemid 15013857)
38. Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A (1997) Autoradiographic distribution of M1, M2, M3, and M4 mus-carinic receptor subtypes in Alzheimer's disease. Synapse 26, 341-350. (Pubitemid 27284105)
39. Whitehouse PJ, Au KS (1986) Cholinergic receptors in aging and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10, 665-676. (Pubitemid 17172651)
40. Whitehouse PJ, Kellar KJ (1987) Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders. J Neural Transm Suppl 24, 175-182.
41. Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30, 113-121.
42. Ellis JR, Ellis KA, Bartholomeusz CF, Harrison BJ, Wesnes KA, Erskine FF, Vitetta L, Nathan PJ (2006) Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 9, 175-189. (Pubitemid 43255831)
43. Sunderland T, Tariot P, Murphy DL, Weingartner H, Mueller EA, Cohen RM (1985) Scopolamine challenges in Alzheimer's disease. Psychopharmacology 87, 247-249. (Pubitemid 16253356)
44. Sunderland T, Tariot PN, Weingartner H, Murphy DL, New-house PA, Mueller EA, Cohen RM (1986) Pharmacologic modelling of Alzheimer's disease. Prog Neuropsychophar-macol Biol Psychiatry 10, 599-610.
45. Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ (1992) Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 5, 72-77.
46. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL (1987) Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 44, 418-426. (Pubitemid 17064486)
47. Sunderland T, Tariot PN, Mueller EA, Murphy DL, Weingart-ner H, Cohen RM (1985) Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls. Psy-chopharmacol Bull 21, 676-679. (Pubitemid 16240089)
48. Doody RS (2003) Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry 64, S7.
49. Araujo JA, Chan AD, Winka LL, Seymour PA, Milgram NW (2004) Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination. Psychopharmacology 175, 92-98. (Pubitemid 39215535)
50. Araujo JA, Studzinski CM, Milgram NW (2005) Further evidence for the cholinergic hypothesis of aging and dementia from the canine modelofaging. Prog Neuropsychopharmacol Biol Psychiatry 29, 411-422. (Pubitemid 40417593)
51. Araujo JA, Nobrega JN, Raymond R, Milgram NW (2011) Aged dogs demonstrate both increased sensitivity to scopo-lamine impairment and decreased muscarinic receptor density. Pharmacol Biochem Behav 98, 203-209.
52. Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR, Canfield CJ, Burford RG (2005) Anti-cholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2, 483-492. (Pubitemid 41277760)
53. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK (2005) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2, 281-290. (Pubitemid 40980186)
54. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Larksater M, Winblad B, Zetterberg H, Blennow K, Langstrom B, Nordberg A (2008) Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63, 621-631.
55. Klein J (2007) Phenserine. Expert Opin Investig Drugs 16, 1087-1097. (Pubitemid 47074163)
56. Winblad B, Giacobini E, Frölich L, Bruinsma G, Becker RE, Greig NH (2010) Phenserine efficacy in Alzheimer's disease. J Alzheimers Dis 22, 1201-1208.
57. Greig NH, De ME, Holloway HW, Yu QS, Utsuki T, Perry TA, Brossi A, Ingram DK, Deutsch J, Lahiri DK, Soncrant TT (2000) The experimental Alzheimer drug phenserine: preclin-ical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Suppl, 176-184.
58. Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M (1996) An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302, 13-20. (Pubitemid 26179925)
59. Buccafusco JJ, Terry AV (2004) Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. J Mol Neurosci 24, 85-91. (Pubitemid 41359172)
60. Buccafusco JJ, Terry AV, Webster SJ, Martin D, Hohnadel EJ, Bouchard KA, Warner SE (2008) The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology 199, 481-494. (Pubitemid 351938233)
61. Higgins GA, Enderlin M, Fimbel R, Haman M, Grottick AJ, Soriano M, Richards JG, Kemp JA, Gill R (2002) Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia. Eur J Neurosci 15, 1827-1840. (Pubitemid 35471908)
62. Ikari H, Spangler EL, Greig NH, Pei XF, Brossi A, Speer D, Patel N, Ingram DK (1995) Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. Neurore-port 6, 481-484.
63. Ingram DK, Spangler EL, Iijima S, Ikari H, Kuo H, Greig NH, London ED (1994) Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. Life Sci 55, 2037-2049.
64. Janas AM, Cunningham SC, Duffy KB, Devan BD, Greig NH, Holloway HW, Yu QS, Markowska AL, Ingram DK, Spangler EL (2005) The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. Life Sci 76, 1073-1081. (Pubitemid 40037530)
65. Patel N, Spangler EL, Greig NH, Yu QS, Ingram DK, Meyer RC (1998) Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuroreport 9, 171-176. (Pubitemid 28046677)
66. Rupniak NM, Tye SJ, Field MJ (1997) Enhanced performance of spatial and visual recognition memory tasks by the selec-tive acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology 131, 406-410. (Pubitemid 27348708)
67. Araujo JA, Studzinski CM, Head E, Cotman CW, Milgram NW (2005) Assessment of nutritional interventions for modification of age-associated cognitive decline using a canine model of human aging. Age 27, 27-37. (Pubitemid 43971791)
68. Milgram NW, Head E, Zicker SC, Ikeda-Douglas CJ, Mur-phey H, Muggenberg B, Siwak C, Tapp D, Cotman CW (2005) Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol Aging 26, 77-90. (Pubitemid 39600593)
69. Ebert U, Kirch W (1998) Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28, 944-949. (Pubitemid 28521587)
70. Dawson GR, Iverson SD (1993) The effect of novel cholin-esterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 57, 143-153. (Pubitemid 24027144)
71. Kirkby DL, Jones DN, Barnes JC, Higgins GA (1996) Effects of anticholinesterase drugs tacrine and E2020, the 5-HT (3) antagonist ondansetron, and the H (3) antagonist thi-operamide, in models of cognition and cholinergic function. Behav Pharmacol 7, 513-525. (Pubitemid 27046781)
72. Poorheidari G, Stanhope KJ, Pratt JA (1998) Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits inthe delayed matchingto position taskinrats:acomparison with the cholinesterase inhibitor E2020. Psychopharmacology 135, 242-255. (Pubitemid 28055459)
73. Iijima S, Greig NH, Garofalo P, Spangler EL, Heller B, Brossi A, Ingram DK (1993) Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology 112, 415-420. (Pubitemid 23324161)
74. Milgram NW, Siwak-Tapp CT, Araujo J, Head E (2006) Neu-roprotective effects of cognitive enrichment. Ageing Res Rev 5, 354-369.
75. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, Wallace WC (1997) Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res 46, 161-168. (Pubitemid 27214367)
76. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH (2000) Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand Suppl, 176-177.
77. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH (2007) The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320, 386-396. (Pubitemid 46025753)
78. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH (2001) Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 98, 7605-7610. (Pubitemid 32567995)
79. Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, Rogers JT (2004) The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann N YAcad Sci 1035, 34-48. (Pubitemid 40362325)
80. Dodart JC, Mathis C, Ungerer A (2000) The beta-amyloid precursor protein and its derivatives: from biology to learning and memory processes. Rev Neurosci 11, 75-93. (Pubitemid 30133162)
81. Holscher C, Gengler S, Gault VA, Harriott P, Mallot HA (2007) Soluble beta-amyloid [25-35] reversibly impairs hip-pocampal synaptic plasticity and spatial learning. Eur J Pharmacol 561, 85-90. (Pubitemid 46435857)
82. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
83. Yamaguchi Y, Kawashima S (2001) Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol 412, 265-272. (Pubitemid 32144942)
84. Utsuki T, Yu QS, Davidson D, Chen D, Holloway HW, Brossi A, Sambamurti K, Lahiri DK, Greig NH, Giordano T (2006) Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther 318, 855-862. (Pubitemid 44061261)
85. Becker RE, Greig NH (2010) Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 7, 642-651.
86. Buccafusco JJ (2008) Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders. J Alzheimers Dis 15, 709-720.
87. Yuede CM, Dong H, Csernansky JG (2007) Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol 18, 347-363. (Pubitemid 47356364)
88. Foster RH, Plosker GL (1999) Donepezil. Pharmacoeconomic implications of therapy. Pharmacoeconomics 16, 99-114.
89. Weinstock M (1997) Possible role of the cholinergic system and disease models. J Neural Transm Suppl, 49-102.
90. Cotman CW, Head E (2008) The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis 15, 685-707.
91. Fisher A (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics 5, 433-442. (Pubitemid 351952486)
92. Pakaski M, Kalman J (2008) Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neu-rochem Int 53, 103-111.
93. Pakaski M, Kasa P (2003) Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Targets CNS Neurol Disord 2, 163-171.
94. Landsberg G, Araujo JA (2005) Behavior problems in geriatric pets. Vet Clin North Am Small Anim Prac 35, 675-698.
95. Landsberg G (2006) Therapeutic options for cognitive decline in senior pets. J Am Anim Hosp Assoc 42, 407-413. (Pubitemid 46403545)
96. Matsui K, Taniguchi S, Yoshimura T (1999) Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. Xenobiotica 29, 1059-1072.